Afficher la notice abrégée

dc.contributor.authorRuiz Beltrán, R.
dc.contributor.authorHerrero Herrero, José Ignacio 
dc.date.accessioned2026-01-22T10:07:07Z
dc.date.available2026-01-22T10:07:07Z
dc.date.issued1992-05
dc.identifier.citationRuiz Beltrán, & Herrero Herrero. (1992). Evaluation of ciprofloxacin and doxycycline in the treatment of mediterranean spotted fever. European Journal of Clinical Microbiology & Infectious Diseases, 11(5), 427-431. https://doi.org/10.1007/BF01961857es_ES
dc.identifier.issn0934-9723
dc.identifier.urihttp://hdl.handle.net/10366/169172
dc.description.abstract[EN]A comparison was made of the results obtained with ciprofloxacin (750 mg/12 h) and doxycycline (100 mg/12 h), both administered p.o. for one week, in 34 and 36 patients respectively with Mediterranean spotted fever. Apyrexia was achieved after 50.1 +/- 34.2 h (mean +/- SD) of antibiotic therapy in the group of patients treated with ciprofloxacin and in 55.2 +/- 23.3 h in the group treated with doxycycline (no significant statistical differences). Resolution of the remaining signs and symptoms of the disease was achieved faster with ciprofloxacin. Both therapeutic regimens were effective and safe. Although more expensive than doxycycline, ciprofloxacin is a bactericidal compound which is better tolerated and has a lower risk of toxicity and of development of resistance. It can be considered, together with doxycycline, as an antibiotic of first choice in the treatment of Mediterranean spotted fever.es_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectMediterranean spotted feveres_ES
dc.subjectBoutonneuse feveres_ES
dc.subjectCiprofloxacines_ES
dc.subjectDoxycyclinees_ES
dc.subjectRickettsia conoriies_ES
dc.subject.meshDoxycycline *
dc.subject.meshBoutonneuse Fever *
dc.subject.meshHumans *
dc.subject.meshCiprofloxacin *
dc.subject.meshDrug Evaluation *
dc.titleEvaluation of ciprofloxacin and doxycycline in the treatment of Mediterranean spotted feveres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1007/BF01961857es_ES
dc.subject.unesco32 Ciencias Médicases_ES
dc.identifier.doi10.1007/BF01961857
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccesses_ES
dc.identifier.pmid1425713
dc.journal.titleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiologyes_ES
dc.volume.number11es_ES
dc.issue.number5es_ES
dc.page.initial427es_ES
dc.page.final431es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decshumanos *
dc.subject.decsfiebre botonosa *
dc.subject.decsdoxiciclina *
dc.subject.decsevaluación de medicamentos *
dc.subject.decsciprofloxacina *


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Attribution-NonCommercial-NoDerivatives 4.0 Internacional